These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8627854)

  • 1. p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma.
    Prendergast NJ; Atkins MR; Schatte EC; Paulson DF; Walther PJ
    J Urol; 1996 May; 155(5):1685-92. PubMed ID: 8627854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 protein and gene alterations in pathological stage C prostate carcinoma.
    Salem CE; Tomasic NA; Elmajian DA; Esrig D; Nichols PW; Taylor CR; Skinner DG; Roy-Burman P; Lieskovsky G; Cote RJ
    J Urol; 1997 Aug; 158(2):510-4. PubMed ID: 9224335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy.
    Cheng L; Sebo TJ; Cheville JC; Pisansky TM; Slezak J; Bergstralh EJ; Pacelli A; Neumann RM; Zincke H; Bostwick DG
    Cancer; 1999 Mar; 85(6):1293-9. PubMed ID: 10189134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An uncertain role for p53 gene alterations in human prostate cancers.
    Brooks JD; Bova GS; Ewing CM; Piantadosi S; Carter BS; Robinson JC; Epstein JI; Isaacs WB
    Cancer Res; 1996 Aug; 56(16):3814-22. PubMed ID: 8706029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
    Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
    Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 mutation is infrequent in clear cell carcinoma of the ovary.
    Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
    Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of p53 mutations with metastatic prostate cancer.
    Eastham JA; Stapleton AM; Gousse AE; Timme TL; Yang G; Slawin KM; Wheeler TM; Scardino PT; Thompson TC
    Clin Cancer Res; 1995 Oct; 1(10):1111-8. PubMed ID: 9815901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 gene alterations in prostate cancer after radiation failure and their association with clinical outcome: a molecular and immunohistochemical analysis.
    Rakozy C; Grignon DJ; Li Y; Gheiler E; Gururajanna B; Pontes JE; Sakr W; Wood DP; Sarkar FH
    Pathol Res Pract; 1999; 195(3):129-35. PubMed ID: 10220791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
    Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
    Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 immunoreactivity in primary and metastatic prostatic adenocarcinoma.
    Hughes JH; Cohen MB; Robinson RA
    Mod Pathol; 1995 Jun; 8(5):462-6. PubMed ID: 7675761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation-induced cutaneous carcinoma of the head and neck: is there an early role for p53 mutations?
    Franchi A; Massi D; Gallo O; Santucci M; Porfirio B
    Clin Exp Dermatol; 2006 Nov; 31(6):793-8. PubMed ID: 16824052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
    Tamboli P; Amin MB; Xu HJ; Linden MD
    Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarcomatoid carcinoma of the prostate: progression from adenocarcinoma is associated with p53 over-expression.
    Delahunt B; Eble JN; Nacey JN; Grebe SK
    Anticancer Res; 1999; 19(5B):4279-83. PubMed ID: 10628387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma.
    Safran H; King T; Choy H; Gollerkeri A; Kwakwa H; Lopez F; Cole B; Myers J; Tarpey J; Rosmarin A
    Cancer; 1996 Sep; 78(6):1203-10. PubMed ID: 8826941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53.
    Stricker HJ; Jay JK; Linden MD; Tamboli P; Amin MB
    Urology; 1996 Mar; 47(3):366-9. PubMed ID: 8633403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of bcl-2, p53, and p21 in benign and malignant prostatic tissue before and after radiation therapy.
    Rakozy C; Grignon DJ; Sarkar FH; Sakr WA; Littrup P; Forman J
    Mod Pathol; 1998 Sep; 11(9):892-9. PubMed ID: 9758370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
    Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
    Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity.
    Grossfeld GD; Olumi AF; Connolly JA; Chew K; Gibney J; Bhargava V; Waldman FM; Carroll PR
    J Urol; 1998 May; 159(5):1437-43. PubMed ID: 9554329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors.
    Meyers FJ; Gumerlock PH; Chi SG; Borchers H; Deitch AD; deVere White RW
    Cancer; 1998 Dec; 83(12):2534-9. PubMed ID: 9874460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.